title: Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
abstract: Bortezomib is a potent, selective proteasome inhibitor. It is usually well tolerated, and bortezomib-induced skin lesions are less well known. A 59-year-old man with multiple myeloma underwent autologous hematopoetic stem cell transplantation (AHSCT). Administration of bortezomib was started after AHSCT as his disease progressed despite thalidomide maintenance. He developed a rash afer the third cycle of bortezomib. A biopsy showed superficial and deep perivascular dermatitis. The rash resolved within 4 days; complete response of myeloma was obtained after 8 cycles of bortezomib. The benign clinical course did not require interruption of the treatment, which in turn resulted in complete remission of myeloma.
authors: Hematology Department, Gazi University Faculty of Medicine, Ankara, Turkey. zubeydenurozkurt@yahoo.com
authors: Zübeyde Nur
authors: ZN
authors: Ozkurt
authors: Gülsan Türköz
authors: GT
authors: Sucak
authors: Sahika Zeynep
authors: SZ
authors: Aki
authors: Münci
authors: M
authors: Yağci
authors: Ozlem
authors: O
authors: Erdem
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001706:Biopsy; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000069286:Bortezomib; D003875:Drug Eruptions / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D005076:Exanthema / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib